Treatment Trials

3 Clinical Trials for Various Conditions

Focus your search

      ACTIVE_NOT_RECRUITING
      Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
      Description

      This phase III trial studies cabozantinib to see how well it works compared with placebo in treating patients with neuroendocrine or carcinoid tumors that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Cabozantinib is a chemotherapy drug known as a tyrosine kinase inhibitor, and it targets specific tyrosine kinase receptors, that when blocked, may slow tumor growth.

      Conditions
      Carcinoid TumorFunctioning Pancreatic Neuroendocrine TumorIntermediate Grade Lung Neuroendocrine NeoplasmLocally Advanced Digestive System Neuroendocrine NeoplasmLocally Advanced Digestive System Neuroendocrine Tumor G1Locally Advanced Lung Neuroendocrine NeoplasmLocally Advanced Pancreatic Neuroendocrine TumorLocally Advanced Unresectable Digestive System Neuroendocrine NeoplasmLow Grade Lung Neuroendocrine NeoplasmLung Neuroendocrine TumorLung Neuroendocrine Tumor G2Metastatic Digestive System Neuroendocrine NeoplasmMetastatic Digestive System Neuroendocrine Tumor G1Metastatic Lung Neuroendocrine NeoplasmMetastatic Lung Neuroendocrine TumorMetastatic Pancreatic Neuroendocrine NeoplasmMetastatic Pancreatic Neuroendocrine TumorMetastatic Thymus Neuroendocrine NeoplasmNeuroendocrine NeoplasmNeuroendocrine Tumor G2Non-Functioning Pancreatic Neuroendocrine TumorPancreatic Serotonin-Producing Neuroendocrine TumorThymus Neuroendocrine TumorUnresectable Digestive System Neuroendocrine NeoplasmUnresectable Digestive System Neuroendocrine Tumor G1Unresectable Lung Neuroendocrine NeoplasmUnresectable Pancreatic Neuroendocrine NeoplasmUnresectable Thymus Neuroendocrine Neoplasm
      Talk to us
      COMPLETED
      Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)
      Description

      This study aimed to investigate the efficacy and safety of PDR001 in patients with advanced or metastatic, well-differentiated, non-functional neuroendocrine tumors of pancreatic, gastrointestinal (GI), or thoracic origin or poorly-differentiated gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC) that progressed on prior treatment.

      Conditions
      Well-differentiated Non-functional NET of Thoracic OriginWell-differentiated Non-functional NET of Gastrointestinal OriginWell-differentiated Non-functional NET of Pancreatic OriginPoorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma
      Talk to us
      COMPLETED
      Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero- Pancreatic Endocrine Tumour
      Description

      The primary purpose of this extension study was to assess the long term safety of patients with nonfunctioning enteropancreatic neuroendocrine tumour (NET), who were treated with open label lanreotide Autogel (120 mg every 28 days) and who participated in a previous study, 2-55-52030-726 (NCT00353496).

      Conditions
      Non Functioning Entero-pancreatic Endocrine Tumour
      Talk to us